A detailed history of Castleark Management LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Castleark Management LLC holds 27,290 shares of KRYS stock, worth $5.2 Million. This represents 0.21% of its overall portfolio holdings.

Number of Shares
27,290
Previous 28,280 3.5%
Holding current value
$5.2 Million
Previous $5.19 Million 4.45%
% of portfolio
0.21%
Previous 0.22%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$174.7 - $213.66 $172,953 - $211,523
-990 Reduced 3.5%
27,290 $4.96 Million
Q2 2024

Aug 13, 2024

SELL
$153.12 - $183.64 $36,748 - $44,073
-240 Reduced 0.84%
28,280 $5.19 Million
Q1 2024

May 15, 2024

SELL
$108.01 - $179.35 $413,678 - $686,910
-3,830 Reduced 11.84%
28,520 $5.07 Million
Q4 2023

Feb 14, 2024

BUY
$96.0 - $128.29 $2.01 Million - $2.69 Million
20,930 Added 183.27%
32,350 $4.01 Million
Q3 2023

Nov 15, 2023

BUY
$108.51 - $130.22 $1.24 Million - $1.49 Million
11,420 New
11,420 $1.32 Million

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.89B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Castleark Management LLC Portfolio

Follow Castleark Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Castleark Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Castleark Management LLC with notifications on news.